[1] LYONS T G. Targeted therapies for triple-negative breast cancer[J].Curr Treat Options Oncol,2019,20(11):82-95.
[2] 杨蕾,徐福霞,程玲慧. FBXO31基因对宫颈癌细胞增殖的影响[J].基因组学与应用生物学,2019,38(8):3746-3750.
[3] LV Z D,WANG H B,LIU X P,et al. Silencing of Prrx2 inhibits the invasion and metastasis of breast cancer both in vitro and in vivo by reversing epithelial-mesenchymal transition[J].Cell Physiol Biochem,2017,42(5):1847-1856.
[4] 中国抗癌协会. 乳腺癌诊治指南与规范(2015 版)[J].中国癌症杂志,2015,25(9):692-754.
[5] 裔莎,魏兵,杨雯娟,等. 美国癌症联合会乳腺癌分期(第七版)简介[J].中华病理学杂志,2010,39(11):787-790.
[6] JHAN J R,ANDRECHEK E R. Triple-negative breast cancer and the potential for targeted therapy[J].Pharmacogenomics,2017,18(17):1595-1609.
[7] 刘志敏,柏斗胜,张弛,等. HECT型E3泛素连接酶在肿瘤中作用的研究现状和进展[J].国际外科学杂志,2020,47(2):135-138.
[8] KHAN M,MUZUMDAR D,SHIARS A. Attenuation of tumor suppressive function of fbxo16 ubiquitin ligase activates wnt signaling in glioblastoma[J].Neoplasia,2019,21(1):106-116.
[9] MANNE R K,AGRAWAL Y,BARGALE A,et al. A MicroRNA/Ubiquitin ligase feedback loop regulates slug-mediated invasion in breast cancer[J].Neoplasia,2017,19(6):483-495.
[10] TAN Y,LIU D,GONG J,et al. The role of F-box only protein 31 in cancer[J].Oncol Lett,2018,15(4):4047-4052.
[11] 王杰,向德兵,唐瑶,等. FBXO31与细胞周期蛋白D1在结直肠腺癌中的表达及临床意义[J].重庆医学,2019,48(3):420-422.
[12] JUANG Y L,JENG Y M,CHEN C L,et al. PRRX2 as a novel TGF-β-induced factor enhances invasion and migration in mammary epithelial cell and correlates with poor prognosis in breast cancer[J].Mol Carcinog,2016,55(12):2247-2259.
[13] 吕志栋,杨召川,金丽英,等. 沉默同源异型盒基因2表达对乳腺癌增殖的影响及其分子机制[J].中华医学杂志,2020,100(12):942-946.
2022, Vol. 39 
